Research on HIV Treatment Strategies: Archive 1994-1999

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

1999 | 1998 | 1997 | 1996 | 1994-95

Show Archived (Historical) Articles

1999

Rapid Rebound of HIV and Reappearance of HIV Reservoirs in Patients Treated with IL-2 and Combination Antiretroviral Drugs Following Cessation of Therapy (October 27, 1999)
From U.S. National Institute of Allergy and Infectious Diseases
New Model Suggests that AIDS Drugs May Not Abolish HIV Infection (October 6, 1999)
From U.S. National Institute of Allergy and Infectious Diseases
Advances in Research: Second & Third Line Therapy (September 1999)
In Project Inform Perspective, from Project Inform
Going Wild (Type) with Structured Treatment Interruptions (STIs) (September/October 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Mycophenylate -- A Potential New Option (September 1999)
In Project Inform Perspective, from Project Inform
Community Alert: Experimental Drug Combinations (August 1999)
From Project Inform
Community Alert: Experimental Drug Dosing Schemes with Protease Inhibitors (August 1999)
From Project Inform
Maintenance Therapy for HIV (June 1999)
In Body Positive, from Body Positive
CD4 Nadir and Disease Progression (April 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
A Three-Drug Combination is the Minimum Standard of Care (Spring 1999)
In Women Alive Newsletter, from Women Alive
Continual Suppression to Yield to Pulsed Therapy? (March, 1999)
From Treatment Action Group
Strategy Trials: The Answer? (February 18, 1999)
From AIDS Treatment News
HIV-Specific Immunity: Major Conference Sessions (February 12, 1999)
From AIDS Treatment News
Phase I/II Dosing Study of Once-Daily Hydroxyurea Alone vs Didanosine Alone vs ddI + HU (February 9, 1999)
Summary by Donald L. Kaminsky, M.D.
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Phase III, Multicenter, Randomized, Open-Label Study to Compare the Antiretroviral Activity and Tolerability of Efavirenz (EFV) + Indinavir (IDV), versus EFV + Zidovudine (ZDV) + Lamuvidine (3TC), versus IDV + ZDV + 3TC at 48 Weeks (Study DMP 266-006) (February 4, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Randomized Trial of Abacavir in Combination with Indinavir and Efavirenz in HIV-Infected Patients with NRTI Experience (February 4, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
ACTG 364: Virologic Efficacy of Nelfinavir (NFV) and/or Efavirenz (EFZ) in Combination with New Nucleoside Analogs in Nucleoside Experienced Subjects (February 3, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Long Term Response to Combination Therapy Commenced Early in HIV Infection: 3 Year Follow-Up: What's Happened Since Vancouver? (February 3, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Co-Administration of Indinavir 1200 mg with Nelfinavir 1250 mg in a Twice Daily Regimen: Preliminary Safety, PK Activity (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Phase I/II Dosing Study of Once-Daily Hydroxyurea Alone vs Didanosine Alone vs ddI + HU (February 2, 1999)
Summary by Kent Sepkowitz, M.D.
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Treatment with d4T + ddI + Nelfinavir + Hydroxyurea for Early or Recent Primary HIV Infection (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Viral Fitness in Patients with Discordant CD4 and Plasma HIV RNA following Protease Inhibitor Failure (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Choosing the Right Initial Antiretroviral Regimens (February 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Mutations in the Reverse Transcriptase Genome of HIV I Isolates Derived from Subjects Treated with Didanosine and Stavudine in Combination (February 1, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Trials & Errors: Studies Look at Which Combinations Are Better (February 1999)
Clinical trials using NNRTIs with or instead of protease inhibitors.
From Seattle Treatment Education Project
1999: Treatments, Issues to Watch (January 8, 1999)
From AIDS Treatment News
Robert Gallo Calls for New Treatment Approach (January 8, 1999)
From AIDS Treatment News

1998

If Silence = Death, Will Numbers = Answers? (December 1998)
In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
Treatment with IL-2 Plus HAART Markedly Reduces HIV in Immune System "Hiding Places" (November 15, 1998)
From U.S. National Institute of Allergy and Infectious Diseases
Studies End Hopes of Reducing Complex Regimen of AIDS Drugs (November 7, 1998)
By Scott Gottlieb.
In British Medical Journal
Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration (November 4, 1998)
The results of The Multicenter AIDS Cohort Study.
In Journal of the American Medical Association
Five-drug regimen produces sharp reductions in viral load (October, 1998)
In HIV Newsline, from San Francisco General Hospital
Simultaneous initiation of three-drug regimen more effective than adding drugs sequentially (October, 1998)
In HIV Newsline, from San Francisco General Hospital
d4T, ddI and nevirapine (NVP) in antiretroviral-naive patients: a convenient triple regimen (September 26, 1998)
In The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Treatment of Primary HIV Infection with Zidovudine, Lamivudine and Indinavir: A Case-Control Study (September 25, 1998)
In The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
The CHORUS Database on Patient Clinical Care -- and Interview with Stephen Becker, M.D. (August 21, 1998)
From AIDS Treatment News
Antiviral Effect of AZT versus D4T in Combination with 3TC and Indinavir in the Context of a Population-Based Study (July 2, 1998)
In The 12th International AIDS Conference, from The Body PRO
Co-Administration of Indinavir 1000mg and Escalating Nelfinavir Dose in a Twice-Daily Regimen: Preliminary Safety, Pharmacokinetic and Antiviral Activity (June 30, 1998)
In The 12th International AIDS Conference, from The Body PRO
Combining Indinavir with Ritonavir (June 30, 1998)
In The 12th International AIDS Conference, from The Body PRO
Efficacy of the Combination of Stavudine (d4T), Didanosine (ddI), and Nevirapine (NVP) as Initial Antiretroviral Therapy and Following Treatment with HIV-1 Protease Inhibitors (June 30, 1998)
In The 12th International AIDS Conference, from The Body PRO
How to Start Antiretroviral Therapy (June 29 and 30, 1998)
Summaries of studies on initial combinations.
In The 12th International AIDS Conference, from The Body PRO
Pharmacokinetic Interaction Between Nevirapine and Indinavir and Correlation with Antiviral Activity (June 30, 1998)
In The 12th International AIDS Conference, from The Body PRO
Combination Abacavir (1592, ABC)/Amprenavir (141W94) Therapy in HIV-1 Infected Antiretroviral Na´ve Subjects with CD4+ Cell Counts >400 cells/mL and Viral Load >5000 copies/mL (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
Does Sequential Therapy Offer Any Advantage Over Continuous Therapy? (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
Indinavir in Combination with Zidovudine (ZDV) and Lamuvidine (3TC) in Treatment-Na´ve Patients with >500 CD4 Cells/mm³ (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
Sixteen-Week Followup of Indinavir Sulfate (Crixivan) Administered Every 8 Hours versus Every 12 Hours in Combination with Efavirenz (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
Summaries of Four Recent Combination Therapy Studies (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
What's the Latest in the Induction/Maintenance Approach to Therapy? (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
Simultaneous vs. Sequential Initiation of Therapy with Indinavir (Crixivan), Zidovudine (AZT) and Lamuvidine (3TC) for HIV Infection: 100 Week Follow-Up (June 27, 1998)
In The 12th International AIDS Conference, from The Body PRO
Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance (June 24, 1998)
In Journal of the American Medical Association
U.S. and French Investigators Alike Are 'Shocked, shocked' to Learn of Maintenance Protocol's Failure (April 1998)
From Treatment Action Group
Moods Brighten as Statistics Lighten (March 1998)
Highlights of research reports, from the 5th Conference on Retroviruses and Opportunistic Infections.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Clinical Implications of Virological "Failure" (February 20, 1998)
Interview with Steven Deeks, M.D., San Francisco General Hospital.
In AIDS Treatment News, from AIDS Treatment News
A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count <= 500 cells/mm³ (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Efavirenz + Indinavir (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Therapy with d4T plus 3TC Produces Sustained Undetectable Levels of Plasma HIV RNA in Patients Treated with Reverse Transcriptase Inhibitors for 10 Years (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm³ (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
d4T+3TC Versus AZT+3TC: Shattering the Synergy Story (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The START Trials (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
2, 4, 6, 8, Who's Afraid to Phosphorylate? (February 1998)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Combination d4T and 3TC in Patients with Prior Exposure (February 1998)
In HIV Newsline, from San Francisco General Hospital
The Next Generation of Antiretroviral Agents (February 1998)
In AIDS Care, from San Francisco General Hospital

1997

Drug-Drug Interactions: An Update (December 1997)
In HIV Newsline, from San Francisco General Hospital
The Next Generation of Antiretroviral Agents -- An Update (December 1997)
In HIV Newsline, from San Francisco General Hospital
Sometimes Less is More (November 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Delavirdine Combination and Viral Load (October 17, 1997)
In AIDS Treatment News, from AIDS Treatment News
Double Protease Inhibitor Combinations (September 28-October 1, 1997)
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
HIV Late Breakers I (September 28-October 1, 1997)
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Impact of Highly Active Antiretroviral Therapy on Opportunistic Infections (3 abstracts) (September 28-October 1, 1997)
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Low Key Dual Combo Appears First to Achieve the Unimaginable (October, 1997)
From Treatment Action Group
Saquinavir Soft Gel Capsules Versus Indinavir as Part of AZT and 3TC Containing Triple Therapy (September 28-October 1, 1997)
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
A Study to Evaluate the Clinical and Virologic Efficacy of a Crixivan, DDI, and D4T Combination (September 1997)
In The 35th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Antioxidants May Still Have a Role in HIV Treatment (September 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
ACTG 300 Leaves Many Questions Unanswered (July/August 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Limited Immune Recovery After Treatment with Antiretrovirals, IL-2: Interview with Clifford Lane, M.D. (June 1997)
From AIDS Treatment News
How Far Can You Knock Down HIV?: An Interview with David D. Ho, MD (June 1997)
In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
Government Study Finds Protease Based Triple Combination Keeps Patients Alive Longer Than Double Nuke (April 1997)
From Treatment Action Group
The Need for 'Strategy' Type Clinical Studies (March 1997)
From Treatment Action Group
Druthers, Grim: Tales of Multiply Resistant HIV (February 7, 1997)
From Treatment Action Group
Staring into the Precipice: Resistance and Cross-Resistance Among Protease Inhibitors (February 7, 1997)
From Treatment Action Group
Antiretroviral Drug Interaction Studies Show Favorable Effects (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
AZT Resistance Predicts Poor Outcome (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
d4T and 3TC Combination Studies Confirm the Effect of the Combination (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
ddI + d4T Combination Therapy Proves Effective (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Protease Combinations May Be the Most Effective (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Ritonavir-Saquinavir Combination Therapy in Patients with Advanced HIV Infection (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Triple Combination Therapy Including Indinavir Is Effective in Advanced AIDS (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

1996

d4T+AZT -- Unexpected CD4 Drop Seen in Study (December 20, 1996)
In AIDS Treatment News, from AIDS Treatment News
Nevirapine's Effect on Indinavir Levels (December 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
The Rationale for Combination Therapy (December 1996)
In HIV Newsline, from San Francisco General Hospital
Large Combination Trials with AZT, ddI, ddC: Results Published (October 18, 1996)
In AIDS Treatment News, from AIDS Treatment News
Early Treatment Choices and Their Unintended Consequences (Hitting it Early, Hard) (October 1996)
In TAGline, from Treatment Action Group
Recipes for Failure (October 1996)
'Early' is right, they say, unless of course your regimen's wrong.
In TAGline, from Treatment Action Group
TAG interviews Dr. David Ho on the effect of the new antiretroviral combinations over time (October, 1996)
From Treatment Action Group
When Highly Active Antiretroviral Therapy (HAART) is Not Enough (October, 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
ddI plus d4T (September 6, 1996)
In AIDS Treatment News, from AIDS Treatment News
Antiretroviral Therapy (September 1996)
In Hopkins HIV Report, from Johns Hopkins AIDS Service
Can HIV Be Cured? (September 1996)
In Hopkins HIV Report, from Johns Hopkins AIDS Service
Delavirdine/Protease Inhibitor Interactions (September 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Snapshots of the Literature (September 1996)
In Hopkins HIV Report, from Johns Hopkins AIDS Service
Five-Drug or Six-Drug Antiretroviral Therapy -- Conversation with Steven Scheibel, M.D. (August 23, 1996)
In AIDS Treatment News, from AIDS Treatment News
Aaron Diamond's Dynamic Duo: The Latest Word on Protease Resistance (August/September 1996)
Treatment Activists Sit Down with Vancouver High Fliers, Try to Make Sense Out of the New Cries of 'Eureka' .
In TAGline, from Treatment Action Group
Another Call for Strategy Trials (August 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
AZT/3TC Clinical Endpoint Analyses (August 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Data from Protease Inhibitor Combination Trials Shows Sustained Benefit (August 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
More Information on Hydroxyurea (August 1996)
In combination with ddI.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Nipping HIV in the Bud (August 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Expert Panel's New Recommendations for Antiviral Treatment (July 19, 1996)
In AIDS Treatment News, from AIDS Treatment News
New View of Antiretroviral Treatment: Illustrations from "Late Breaker" Abstracts (July 19, 1996)
In AIDS Treatment News, from AIDS Treatment News
Snapshots of the Literature (July 1996)
In Hopkins HIV Report, from Johns Hopkins AIDS Service
Clinically Clueless: Keystone Group Addresses Crisis in Post-Marketing Treatment Research and Access to FDA-Approved Therapies (June 1996)
In TAGline, from Treatment Action Group
Immunologic Factors & Therapy (report from the XIth International AIDS Conference) (Summer 1996)
In STEP Perspective, from Seattle Treatment Education Project
Throw Down Your Crutches and Walk (June/July 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Viral Eradication (report from the XIth International AIDS Conference) (Summer 1996)
In STEP Perspective, from Seattle Treatment Education Project
Viral Resistance (report from the XIth International AIDS Conference) (Summer 1996)
In STEP Perspective, from Seattle Treatment Education Project
Comparing the (RTI) Combinations: Reported maximum average reductions in plasma HIV RNA with selected RTI combination regimens (in treatment naive individuals) (April 1996)
In TAGline, from Treatment Action Group
Looking into the Future of HIV Therapy: An Interview with Dr. David Cooper (March, 1996)
In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
Snapshots of the Literature (March 1996)
In Moore News for Care Providers, from Johns Hopkins AIDS Service
Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating HIV (March 1, 1996)
In AIDS Treatment News, from AIDS Treatment News
d4T Plus ddI Antiviral Results (February 1996)
In AIDS Treatment News, from AIDS Treatment News

1994-95

Lamivudine Approved for Combination Use with AZT (December 1, 1995)
In AIDS Treatment News, from AIDS Treatment News
New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment (December 1, 1995)
In AIDS Treatment News, from AIDS Treatment News
San Francisco Area: Testosterone Replacement Study, Injection vs. Patch (October 20, 1995)
In AIDS Treatment News, from AIDS Treatment News
AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone (October 6, 1995)
In AIDS Treatment News, from AIDS Treatment News
Nucleoside Analogue Drug Combinations (October, 1995)
From American Foundation for AIDS Research
ACTG 175: Anti-HIV Therapy Lowers Risk of AIDS, Death in Patients with Intermediate-Stage HIV Disease (September 1995)
From U.S. National Institute of Allergy and Infectious Diseases
Hydroxyurea and ddI: French Study Published (September 1, 1995)
In AIDS Treatment News, from AIDS Treatment News
New Antiretroviral Strategies: Interview with Marcus Conant, M.D. (August 4, 1995)
In AIDS Treatment News, from AIDS Treatment News
Report on Drug Development from the HIV Immune-based Therapies Workshop (March 1995)
In TAGline, from Treatment Action Group
The Intra-Company Cooperative Triple Drug Combination (June 1994)
In TAGline, from Treatment Action Group

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.